Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Sponsor: Boehringer Ingelheim
Terminated
Substance discontinued
Other terminated trials from Boehringer Ingelheim
Other Arthritis, Rheumatoid trials with similar outcome
This PHASE3 trial investigates Arthritis, Rheumatoid and is currently terminated or withdrawn. Boehringer Ingelheim leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Sep 2020 [monthly]
Terminated PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Nov 2017 — Feb 2018 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Mar 2017 — Nov 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .